Liposomal amphotericin B: clinical experience and perspectives

References

• Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546–1554 (2003).
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37, 1172–1177 (2003).
   PubMed Web of Science ®Google Scholar
• NNIS System. National nosocomial infection surveillance (NNIS) system report, data summary from January 1990 to May, issued June 1999. Am. J. Infect. Control 27, 520–532 (1999).
   PubMed Web of Science ®Google Scholar
• Hayes-Lattin B, Maziarz RT. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk. Lymph. 45, 669–680 (2004).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr. Opin. Infect. Dis. 16, 533–537 (2003).
   PubMedGoogle Scholar
• Perfect J, Casadevall A. Cryptococcosis. Infect. Dis. Clin. North Am. 16, 837–874 (2002).
   PubMed Web of Science ®Google Scholar
• Denning DW, Marinus A, Cohen J et al. An EORTC multicenter prospective survey of invasive aspergillosis in hematological patients: diagnosis and therapeutic outcome. J. Infect. 37, 173–180 (1998).
   PubMed Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12, 308–329 (1990).
   PubMedGoogle Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new ‘gold standard’. Clin. Infect. Dis. 37, 415–425 (2003).
   PubMed Web of Science ®Google Scholar
• Abelcet®, product information. Enzon Pharmaceuticals, Inc. NJ, USA (2002).
   Google Scholar
• Amphotec®, product information. Intermune, Inc., CA, USA (2001).
   Google Scholar
• AmBisome®, product information. Fujisawa Healthcare, Inc., IL, USA (2000).
   Google Scholar
• Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr. Clin. Top. Infect. Dis. 20, 1–23 (2000).
   PubMedGoogle Scholar
• White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. 27(2), 296–302 (1998).
   PubMed Web of Science ®Google Scholar
• Bowden RA, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35, 359–366 (2002).
   PubMed Web of Science ®Google Scholar
• Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30, 535–541 (1992).
   PubMed Web of Science ®Google Scholar
• Calliot D, Reny G, Solary E et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with hematological malignancies. J. Antimicrob. Chemother. 33, 603–613 (1994).
   PubMedGoogle Scholar
• Pascual B, Ayestaran A, Montoro J et al. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann. Pharmacother. 29, 1197–1201 (1995).
   PubMed Web of Science ®Google Scholar
• Petit N, Parola P, Dhiver C, Gastaut JA. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients. J. Antimicrob. Chemother. 38, 154–157 (1996).
   PubMedGoogle Scholar
• Pappas P, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38, 161–189 (2004).
   PubMed Web of Science ®Google Scholar
• Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30, 710–718 (2000).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Pfaller M, Messer S et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Antimicrob. Chemother. 42, 718–721 (2004).
   Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12, 40–79 (1999).
   PubMed Web of Science ®Google Scholar
• Sporanox® oral solution/injection, product information. Janssen Pharma, NJ, USA (2004).
   Google Scholar
• Sporanox® capsules, product information. Janssen Pharma, NJ, USA (2002).
   Google Scholar
• Herbrect R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36, 198–202 (1998).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev. Anti Infect. Ther. 2(4), 485–497 (2004).
   PubMedGoogle Scholar
• Voriconazole®, product information. Pfizer, Inc., NY, USA (2004).
   Google Scholar
• Dannaoui E, Meletiadis J, Mouton JW, Meis J, Verweij P. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51, 45–52 (2003).
   PubMed Web of Science ®Google Scholar
• Cancidas®, product information. Merck & Co., Inc., NJ, USA (2004).
   Google Scholar
• Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev. Anti Infect. Ther. 2(4), 499–508 (2004).
   Google Scholar
• Higashiyama Y, Kohno S. Micafungin: a therapeutic review. Expert Rev. Anti Infect. Ther. 2(3), 345–355 (2004).
   Google Scholar
• Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. J. Antimicrob. Chemother. 49, 21–30 (2002).
   PubMed Web of Science ®Google Scholar
• Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14(Suppl. 5), S3–S7 (1994).
   Google Scholar
• Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl. S1), 7–10 (2002).
   PubMed Web of Science ®Google Scholar
• Francis P, Lee JW, Hoffman A et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D mannitol and serum galactomannan as markers of infection. J. Infect. Dis. 169, 356–368 (1994).
   PubMed Web of Science ®Google Scholar
• Adler-Moore J, Chiang S, Satorius A et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28(Suppl. B), 63–71 (1991).
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin (Fungizone) for the treatment of paracoccidiodomycosis. J. Med. Vet. Mycol. 31, 387–394 (1993).
   Google Scholar
• Clemons KV, Stevens DA. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32, 465–472 (1993).
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30, 353–363 (1992).
   PubMed Web of Science ®Google Scholar
• Clark JM, Whitney RR, Olsen SJ et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35, 615–621 (1991).
   PubMed Web of Science ®Google Scholar
• Hostetler JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36, 2656–2660 (1992).
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother. 35, 1829–1833 (1991).
   PubMed Web of Science ®Google Scholar
• Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers. J. Clin. Pharmacol. 41, 963–971 (2001).
   PubMed Web of Science ®Google Scholar
• Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23, 279–291 (1992).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Bosse D, Jehn U et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob. Agents Chemother. 41, 1275–1280 (1997).
   PubMed Web of Science ®Google Scholar
• Eldem T, Arican-Cellat N, Agabeyoglu I, Akova M, Kansu E. Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. Int. J. Pharm. 213, 153–161 (2001).
   PubMedGoogle Scholar
• Bekersky I, Fielding RM, Dressler DE et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46, 834–840 (2002).
   PubMed Web of Science ®Google Scholar
• Tollemar J, Ringden O, Tyden G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients: efficacy and safety evaluation. Clin. Transplant. 4, 167–176 (1990).
   Web of Science ®Google Scholar
• Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38, 583–592 (1998).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus spp. and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45, 3487–3496 (2001).
   PubMed Web of Science ®Google Scholar
• Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46, 828–833 (2002).
   PubMed Web of Science ®Google Scholar
• Gubbins PO, McConnell SA, Amsden JR, Anaissie E. Comparison of liposomal amphotericin B plasma and tissue concentrations following a single large (15 mg/kg) dose or daily 1 mg/kg dosing. Proceedings of the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October–2 November 2004 (Abstract A-33).
   Google Scholar
• Adler-Moore J, Proffitt RT. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3, 429–450 (1993).
   Google Scholar
• Groll AH, Giri H, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182, 274–282 (2000).
   PubMed Web of Science ®Google Scholar
• AmBisome®, product characteristics. Gilead Sciences International Ltd, CA, USA (2004).
   Google Scholar
• Heinemann V, Bosse D, Jehn U et al. Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. J. Antimicrob. Chemother. 40, 295–297 (1997).
   PubMed Web of Science ®Google Scholar
• Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41, 1392–1395 (1997).
   PubMed Web of Science ®Google Scholar
• Lewis RE, Lund BC, Klepser ME, Ernst EL. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42, 1382–1386 (1998).
   PubMed Web of Science ®Google Scholar
• Di Bonaventura G, Spedicato I, Picciani C, D’Antonio D, Piccolomini R. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob. Agents Chemother. 48, 4453–4456 (2004).
   PubMed Web of Science ®Google Scholar
• Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 20, 1335–1355 (2000).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Estey E, Raad I et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97, 450–456 (2003).
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 23, 163–168 (1999).
   PubMed Web of Science ®Google Scholar
• Biancofiore G, Bindi ML, Baldassarri R et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transplant. Int. 15, 341–347 (2002).
   PubMed Web of Science ®Google Scholar
• Bennett JE, Powers JH, Walsh TJ et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin. Infect. Dis. 36(Suppl. 3), S117–S122 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 340, 764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz G et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351, 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymph. 40, 511–520 (2001).
   PubMed Web of Science ®Google Scholar
• Juster-Reicher A, Leibovitz E, Linder N et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low-birth-weight infants. Infection 28, 223–226 (2000).
   PubMed Web of Science ®Google Scholar
• Juster-Reicher A, Flidel-Rimon O, Amitay M et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur. J. Clin. Microbiol. Infect. Dis. 22, 603–607 (2003).
   PubMed Web of Science ®Google Scholar
• Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28(Suppl. B), 73–82 (1991).
   PubMed Web of Science ®Google Scholar
• Ruiz I, Olive T, Gavalda J et al. High doses of AmBisome in the treatment of invasive aspergillosis. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 14–17 September 2003 (Abstract M-966).
   Google Scholar
• van der Horst CM, Saag MS, Cloud G et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337, 15–21 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob. Agents Chemother. 48, 693–715 (2004).
   PubMed Web of Science ®Google Scholar
• Coker RJ, Viviani M, Gazzard BG et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7, 829–835 (1993).
   PubMed Web of Science ®Google Scholar
• Viviani M, Rizzardini G, Tortorano AM et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 22, 137–142 (1994).
   PubMedGoogle Scholar
• Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11, 1463–1471 (1997).
   PubMed Web of Science ®Google Scholar
• Hamill R, Sobel JD, El-Sadr W et al. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 26–29 September 1999 (Abstract 1161).
   Google Scholar
• Clemons KV, Stevens DA. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. 42, 899–902 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 137, 105–109 (2002).
   PubMed Web of Science ®Google Scholar
• Seaman J, Boer C, Wilkinson R et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21, 188–193 (1995).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Pandey AK, Sinha GP et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans. R. Soc. Trop. Med. Hyg. 90, 319–322 (1996).
   PubMed Web of Science ®Google Scholar
• Davidson RN, di Martino L, Gradoni L et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22, 938–943 (1996).
   PubMed Web of Science ®Google Scholar
• di Martino L, Davidson RN, Giacchino R et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J. Pediatr. 131, 271–277 (1997).
   PubMed Web of Science ®Google Scholar
• Berman JD, Badaro R, Thakur CP et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. 76, 25–32 (1998).
   PubMed Web of Science ®Google Scholar
• Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int. J. Antimicrob. Agents. 17, 67–70 (2001).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am. J. Trop. Med. Hyg. 66, 143–146 (2002).
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. Br. Med. J. 323, 419–422 (2001).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis. 37, 800–804 (2003).
   PubMed Web of Science ®Google Scholar
• Chowfin A, Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin. Infect. Dis. 969–971 (2000).
   PubMedGoogle Scholar
• Antony S, Dominguez DC, Sotelo E. Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis. J. Natl Med. Assoc. 95, 982–985 (2003).
   PubMed Web of Science ®Google Scholar
• Wang J, Hung C, Chang S, Chueh S, La M. Disseminated Penicillum marneffei infection in a renal-transplant recipient successfully treated with liposomal amphotericin B. Transplantation 76, 1136–1137 (2003).
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and lipsomal amphotericin. Cancer 97, 1025–1032 (2003).
   PubMed Web of Science ®Google Scholar
• Byun R, Siddiqui J, McNeil A, Cohen S. Regression of central nervous system (CNS) aspergillus lesion with combination liposomal amphotericin B and caspofungin in a patient with human immunodeficiency syndrome (HIV) infection. Proceedings of the 40th Meeting of the Infectious Diseases Society of America. 24–27 October 2002 (Abstract 357).
   Google Scholar
• Nguyen HH, Avante CJ, Siddiqui J, King J, Cohen SH. Successful treatment of candidemia with caspofungin and liposomal amphotericin B after failure of monotherapy. Proceedings of the 13th Focus on Fungal Infections Meeting. 19–21 March 2003 (Abstract 40).
   Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Combination therapy studies using AmBisome, amphotericin B deoxycholate, caspofungin, micafungin, and voriconazole against CNS aspergillosis. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October–2 November 2004 (Abstract M-1140).
   Google Scholar
• Ghannoum M, Long L, Yearick D, Isham N. The effect of sequential treatment with AmBisome and voriconazole on the inhibition of Aspergillus fumigatus. Proceedings of the 40th Meeting of the Infectious Diseases Society of America. 24–27 October 2002 (Abstract 356).
   Google Scholar
• Kontoyiannis D, Boktour M, Hanna H, Hachem RY, Raad I. Does itraconazole (ITRA) added to amphotericin B or its lipid formulation (AMB/LPD) improve outcome of primary treatment of invasive aspergillosis (IA)? Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October–2 November 2004 (Abstract M-1032).
   Google Scholar
• Meletiadis J, Petraitis V, Petraitiene R et al. Antagonistic interaction between liposomal amphotericin B and ravuconazole in experimental invasive pulmonary aspergillosis: implications for combination therapy. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 Ocotber–2 November 2004 (Abstract M-238).
   Google Scholar
• Klepser ME. Amphotericin B in lung transplant recipients. Ann. Pharmacother. 36, 167–169 (2002).
   PubMedGoogle Scholar
• Calvo V, Borro J, Morales P et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 115, 1301–1304 (1999).
   PubMed Web of Science ®Google Scholar
• Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant. Proc. 29, 627–628 (1997).
   PubMed Web of Science ®Google Scholar
• Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for aspergillus infection in lung transplantation: study of risk factors. J. Heart Lung Transplant. 20, 1274–1281 (2001).
   PubMed Web of Science ®Google Scholar
• Dubois J, Bartter T, Gryn J, Pratter M. The physiologic effects of inhaled amphotericin B. Chest 108, 750–753 (1995).
   PubMed Web of Science ®Google Scholar
• Erjavec Z, Woolthuis G, Bries-Hospers H. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur. J. Clin. Microbiol. Infect. Dis. 16, 364–368 (1997).
   PubMed Web of Science ®Google Scholar
• Monforte V, Gavalda J, Roman A et al. Pharmacokinetics and efficacy of nebulized AmBisome in lung transplantation. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 Ocotber–2 November 2004 (Abstract M-1042).
   Google Scholar
• Roden MM, Nelson LD, Knudsen TA et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin. Infect. Dis. 36, 1213–1220 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 18, 1053–1061 (1998).
   PubMed Web of Science ®Google Scholar
• Wingard J, White M, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. 31, 1155–1163 (2000).
   PubMed Web of Science ®Google Scholar
• Deray G. Amphotericin B nephrotoxicity. J. Antimicrob. Chemother. 49(Suppl. 1), 37–41 (2002).
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 60, 1452–1459 (2001).
   PubMed Web of Science ®Google Scholar
• Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J. Antimicrob. Chemother. 43, 267–271 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher MA, Talbot GH, Maislin G et al. Risk factors associated with amphotericin B associated nephrotoxicity. Am. J. Med. 87, 547–552 (1989).
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32, 686–693 (2001).
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. 27, 1406–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Mayer J, Doubek M, Doubek J et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J. Infect. Dis. 186, 379–388 (2002).
   PubMed Web of Science ®Google Scholar
• Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomised controlled trial. Br. Med. J. 322, 579–584 (2001).
   PubMed Web of Science ®Google Scholar
• Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis. 36, 943–951 (2003).
   PubMed Web of Science ®Google Scholar
• Ringden O, Andstrom E, Remberger M, Svahn B-M, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant. 14(Suppl. 5), S10–S14 (1994).
   PubMed Web of Science ®Google Scholar
• Drug Topics Red Book. Fleming T (Ed.). Thomson Healthcare PDR, NJ, USA (2004).
   Google Scholar
• Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18, 2476–2483 (2000).
   PubMed Web of Science ®Google Scholar
• Kuti JL, Kotapati S, Williams P et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 22, 301–310 (2004).
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Cagnoni PJ, Wingard JR, Prendergast MM, Tong KB. Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. J. Med. Econ. 5, 109–118 (2002).
   Google Scholar
• Wingard J, Leather HL, Walsh TJ et al. Pharmacoeconomic analysis comparing caspofungin to liposomal amphotericin B for empircal therapy in persistently febrile neutropenic patients. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 Ocotber–2 November 2004 (Abstract O-1619).
   Google Scholar
• Mazzola JL, Belliveau PP, Cheeseman SH. Guidelines for liposomal amphotericin B. Am. J. Health. Syst. Pharm. 60, 1480–1481 (2003).
   PubMedGoogle Scholar